Azura Ophthalmics Announces Positive Topline Results from Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction
Press Release — AZR-MD-001 meets primary endpoints of significant improvement in signs and symptoms of MGD and restoration of gland function — Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced topline results from a phase 2 program evaluating the company’s investigational therapy for […]